Clinical trial

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

NCT00000870

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Indinavir sulfate Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Lamivudine Normalized identity: lamivudineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Stavudine Normalized identity: stavudineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Zidovudine Normalized identity: zidovudineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Didanosine Normalized identity: didanosineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Aldesleukin Normalized identity: aldesleukinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE2

Conditions

HIV Infectionsunresolved

Interventions

Indinavir sulfateDRUG

LamivudineDRUG · verified · RxNorm: lamivudine

StavudineDRUG · verified · RxNorm: stavudine

ZidovudineDRUG · verified · RxNorm: zidovudine

DidanosineDRUG · verified · RxNorm: didanosine

AldesleukinDRUG · verified · RxNorm: aldesleukin

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

Mapped research locations

New YorkNew York, United States4 BostonMassachusetts, United States1 Los AngelesCalifornia, United States1 St LouisMissouri, United States1 SeattleWashington, United States1 ClevelandOhio, United States1 BirminghamAlabama, United States1 ColumbusOhio, United States1 DurhamNorth Carolina, United States1 AuroraColorado, United States1 Chapel HillNorth Carolina, United States1 New OrleansLouisiana, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00000870 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.